title: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
abstract: Immunotherapy, particularly the adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), is a very promising therapy for metastatic melanoma. Some patients unable to receive TIL have been successfully treated with autologous peripheral blood lymphocytes (PBL), genetically modified to express human leukocyte antigen (HLA) class I antigen-restricted, melanoma antigen-reactive T-cell receptors; however, substantial numbers of patients remain ineligible due to the lack of expression of the restricting HLA class I allele. We sought to overcome this limitation by designing a non-MHC-restricted, chimeric antigen receptor (CAR) targeting the high molecular weight melanoma-associated antigen (HMW-MAA), which is highly expressed on more than 90% of human melanomas but has a restricted distribution in normal tissues. HMW-MAA-specific CARs containing an antigen recognition domain based on variations of the HMW-MAA-specific monoclonal antibody 225.28S and a T-cell activation domain based on combinations of CD28, 4-1BB, and CD3zeta activation motifs were constructed within a retroviral vector to allow stable gene transfer into cells and their progeny. Following optimization of the HMW-MAA-specific CAR for expression and function in human PBL, these gene-modified T cells secreted cytokines, were cytolytic, and proliferated in response to HMW-MAA-expressing cell lines. Furthermore, the receptor functioned in both CD4(+) and CD8(+) cells, was non-MHC restricted, and reacted against explanted human melanomas. To evaluate this HMW-MAA-specific CAR in patients with metastatic melanoma, we developed a clinical-grade retroviral packaging line. This may represent a novel means to treat the majority of patients with advanced melanoma, most notably those unable to receive current ACT therapies.
authors.affiliation: Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
authors.forename: William R
authors.initials: WR
authors.lastname: Burns
authors.forename: Yangbing
authors.initials: Y
authors.lastname: Zhao
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Frankel
authors.forename: Christian S
authors.initials: CS
authors.lastname: Hinrichs
authors.forename: Zhili
authors.initials: Z
authors.lastname: Zheng
authors.forename: Hui
authors.initials: H
authors.lastname: Xu
authors.forename: Steven A
authors.initials: SA
authors.lastname: Feldman
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Richard A
authors.initials: RA
authors.lastname: Morgan
mesh_terms: D000483:Alleles; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology; D045744:Cell Line, Tumor; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D011946:Receptors, Antigen / Q000737:chemistry*; D012190:Retroviridae / Q000235:genetics; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D000951:Antigens, Neoplasm; D011946:Receptors, Antigen; D000099216:Chondroitin Sulfate Proteoglycan 4
references.citation: Nat Med. 2008 Nov;14(11):1264-70
references.pmid: 18978797
references.citation: Int J Cancer. 1981 Sep 15;28(3):293-300
references.pmid: 7033148
references.citation: Blood. 2009 Jul 16;114(3):535-46
references.pmid: 19451549
references.citation: Crit Rev Immunol. 2004;24(4):267-96
references.pmid: 15588226
references.citation: Cancer Res. 2008 Oct 1;68(19):8066-75
references.pmid: 18829565
references.citation: J Invest Dermatol. 1999 May;112(5):744-50
references.pmid: 10233766
references.citation: Mol Ther. 2007 Oct;15(10):1744-50
references.pmid: 17637721
references.citation: Mol Ther. 2007 Apr;15(4):825-33
references.pmid: 17299405
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
references.pmid: 17062687
references.citation: Nat Rev Immunol. 2002 Jul;2(7):512-9
references.pmid: 12094225
references.citation: Nat Rev Cancer. 2003 Jan;3(1):35-45
references.pmid: 12509765
references.citation: Int J Cancer. 2003 Jan 20;103(3):399-407
references.pmid: 12471624
references.citation: Nat Rev Cancer. 2008 Apr;8(4):299-308
references.pmid: 18354418
references.citation: J Invest Dermatol. 1985 Oct;85(4):340-6
references.pmid: 3900230
references.citation: Int J Cancer. 1997 Sep 26;73(1):42-9
references.pmid: 9334808
references.citation: J Immunol. 2009 Nov 1;183(9):5563-74
references.pmid: 19843940
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
references.pmid: 8421711
references.citation: Science. 2006 Oct 6;314(5796):126-9
references.pmid: 16946036
references.citation: J Clin Oncol. 2006 May 1;24(13):e20-2
references.pmid: 16648493
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613